2017年4月24日 · WCK 5222 consists of cefepime combined with zidebactam, a bicyclo-acyl hydrazide β-lactam enhancer antibiotic with a dual action involving binding to Gram-negative …

2017年6月1日 · Cefepime combined with zidebactam (WCK 5222) is under clinical development for treatment of Gram-negative infections. Objectives: To evaluate the in vitro activities of …

Zaynich TM, (Zidebactam/Cefepime – WCK 5222) a combination of Zidebactam and Cefepime, is Wockhardt’s novel patented antibiotic, targeted towards multi-drug resistant Gram-negative …

WCK 5222 is an antibiotic in development that combines a currently approved cephalosporin, cefepime, with a novel β-lactam enhancer (BLE), zidebactam. The combination of cefepime …

2025年1月1日 · WCK 5222 is a Phase 3-stage antibiotic that combines bicyclo-acyl hydrazide, zidebactam with cefepime (1 g + 2 g, q8h). Zidebactam is distinct from diaza-bicyclo-octane …

2022年9月30日 · Background: Zidebactam, a bicyclo-acyl hydrazide β-lactam 'enhancer' antibiotic, in combination with cefepime (WCK 5222) is under clinical development for the …

4 天之前 · Objective Treatment option for the infections caused by MBL-producing P. aeruginosa is severely limited. Cefepime/zidebactam (WCK 5222) is a novel β-lactam/ β-lactam-enhancer …

Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine …

WCK 5222 is a novel β-lactam–β-lactam-enhancer combination that elicits rapid bactericidal activity at sub-MICs through simultaneous inactivation of PBP2 (ZID) and PBP3 (FEP).

WCK 5222 is being developed to treat serious Gram-negative bacterial infections which are becoming increasingly resistant to antibiotics and pose a grave threat to public health. This …